Welcome to our dedicated page for Kamada news (Ticker: KMDA), a resource for investors and traders seeking the latest updates and insights on Kamada stock.
Kamada Ltd. develops, produces and markets specialty plasma-derived therapeutics and other biopharmaceutical products for rare and serious conditions. News about KMDA commonly covers financial results and guidance, commercial performance of products such as KAMRAB, GLASSIA, HEPAGAM, VARIZIG, WINRHO and CYTOGAM, and supply arrangements for blood-product markets.
Company updates also address plasma collection operations, including FDA-cleared facilities in Texas, product distribution activity, dividend policy and withholding-tax procedures for ordinary-share distributions. Kamada is traded on Nasdaq and the Tel Aviv Stock Exchange.
Kamada reported strong financial results for Q2 and H1 2024. Revenues for Q2 2024 were $42.5 million, a 13% increase YoY, and $80.2 million for H1 2024, up 18% YoY. Q2 2024 adjusted EBITDA was $9.1 million, a 51% increase YoY, and $16.6 million for H1 2024, up 68% YoY. Net income for Q2 2024 was $4.4 million ($0.08 per share), and $6.8 million ($0.12 per share) for H1 2024. Kamada reiterated its full-year revenue guidance of $158-$162 million and adjusted EBITDA of $28-$32 million. Increased sales of KEDRAB and CYTOGAM in the US market were primary revenue drivers. Operating expenses rose due to higher S&M and R&D costs associated with marketing and the advanced Inhaled AAT clinical trial. Kamada generated $15.0 million of cash from operating activities in H1 2024 and held $56.5 million in cash and equivalents as of June 30, 2024. The company continues to explore new business opportunities and expects double-digit growth beyond 2024.
Kamada (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company specializing in rare and serious conditions and plasma-derived products, has announced its upcoming financial results release. The company will disclose its second quarter and first half 2024 financial results on August 14, 2024, before U.S. financial markets open.
Following the release, Kamada's management will host an investment community conference call at 8:30am Eastern Time on the same day. Shareholders and interested parties can participate via phone or webcast. The call will be archived on the company's website for 90 days.
Kamada reported strong first quarter 2024 financial results with a 23% increase in revenues and a 96% rise in profitability. The company's top-line growth was driven by U.S. sales of KEDRAB® and CYTOGAM®. Kamada increased its full-year revenue guidance to $158-162 million and adjusted EBITDA to $28-32 million. The company remains optimistic about its growth prospects beyond 2024.
Kamada will announce its first quarter 2024 financial results on May 8, 2024, before the U.S. financial markets open. The company, known for its rare condition treatments, will host an investment community conference call to discuss the results.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.